STOCK TITAN

Vanguard disaggregates holdings; reports 0% stake in Zoetis (ZTS)

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Zoetis Inc. Schedule 13G/A amendment shows The Vanguard Group reports no beneficial ownership of Zoetis common stock. The filing, labeled Amendment No. 11, explains an internal realignment effective January 12, 2026 that led certain Vanguard subsidiaries to report holdings separately. The filing states 0 shares beneficially owned and 0% of the class, and is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026. The issuer address is listed as 10 Sylvan Way, Parsippany, NJ.

Positive

  • None.

Negative

  • None.

Insights

Vanguard's internal realignment produced separate reporting; Zoetis stake is reported as zero.

The filing documents that, following the January 12, 2026 realignment, certain Vanguard subsidiaries now report disaggregated positions under SEC Release No. 34-39538. The Schedule 13G/A shows 0% beneficial ownership and zero voting and dispositive power.

Practical implication: holdings previously attributed to The Vanguard Group may now appear under subsidiary filings. Subsequent filings from Vanguard entities should be checked for any nonzero positions attributed to those subsidiaries.

Amendment cites SEC release and clarifies beneficial ownership attribution after reorganization.

The submission relies on SEC Release No. 34-39538 to justify separate reporting by subsidiaries; it affirms that The Vanguard Group "no longer has, or is deemed to have, beneficial ownership" of securities held by those units. The filing records 0 shares and 0% of the class.

Compliance note: this is a disclosure adjustment tied to internal structure. Review related 13G/A or 13D filings from Vanguard affiliates for any transferred beneficial positions to understand aggregate institutional exposure.






98978V103

(CUSIP Number)
03/13/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/27/2026

FAQ

Does The Vanguard Group own any Zoetis (ZTS) shares after this amendment?

No. The Schedule 13G/A amendment states The Vanguard Group beneficially owns 0 shares, representing 0% of the class, as reported in the filing dated 03/27/2026.

Why does Vanguard say subsidiaries will report separately for ZTS?

Because of an internal realignment. The filing references the January 12, 2026 realignment and SEC Release No. 34-39538, directing certain subsidiaries to report beneficial ownership on a disaggregated basis.

Who signed the Schedule 13G/A amendment for Vanguard on Zoetis?

Ashley Grim signed the amendment. The filing is signed by Ashley Grim, Head of Global Fund Administration, with signature date 03/27/2026, attesting to the ownership statements in the submission.

Should investors expect a change in reported institutional holdings for ZTS?

Possibly in subsidiary filings. This amendment shifts reporting to Vanguard subsidiaries; associated 13G/A filings from those affiliates may show positions previously aggregated under The Vanguard Group.

What voting or dispositive power does Vanguard report for ZTS here?

None. The filing shows 0 shares for sole or shared voting power and 0 shares for sole or shared dispositive power, per the Schedule 13G/A.
Zoetis Inc

NYSE:ZTS

View ZTS Stock Overview

ZTS Rankings

ZTS Latest News

ZTS Latest SEC Filings

ZTS Stock Data

49.23B
421.44M
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
PARSIPPANY